Core Viewpoint - The strategic cooperation agreement signed between LianKang Biotechnology Group, Wenzhou Medical University National Engineering Research Center, and the Ouhai District People's Government aims to enhance the group's research and development pipeline in the fields of skin, ophthalmology, and metabolic-related diseases, accelerating the implementation of its strategic goals [1][2]. Group 1 - The collaboration will leverage the strengths of each party in research, industry, and policy to conduct comprehensive cooperation from basic research to clinical transformation and industrialization in the application of growth factor drugs in regenerative medicine [1][2]. - The parties will explore the synergistic mechanisms of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair, with the aim of developing new compound formulations and delivery systems [1][2]. - This partnership is expected to fill treatment gaps in various specific indications and further unlock clinical and commercial value in the extensive chronic disease market [1]. Group 2 - The Wenzhou Medical University National Engineering Research Center, led by Academician Li Xiaokun of the Chinese Academy of Engineering, is a leading independent entity in the field of growth factor drugs, focusing on basic research and new drug development [2]. - The Ouhai District People's Government plays a crucial role in supporting this strategic cooperation, aiming to create a top-tier biopharmaceutical industry ecosystem, providing comprehensive support and policy backing for the collaboration project [2]. - This cooperation is anticipated to enhance the group's research efficiency and success rate in the field of biopharmaceutical innovation, shorten product development cycles, and strengthen its competitive edge in the EGF/FGF segment [2].

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 自願性公佈 聯康集團與溫醫大國家工程研究中心及 溫州市甌海區人民政府達成戰略合作 香港，二零二五年十二月三十日 — 聯康生物科技集團有限公司（「本公司」），連 同其附屬公司統稱（「本集團」）董事會（「董事會」）欣然宣佈，於近日在浙江省溫州 市，本集團與溫州醫科大學細胞生長因子藥物和蛋白製劑國家工程研究中心（「溫 醫 大 國 家 工 程 研 究 中 心 」）及 溫 州 市 甌 海 區 人 民 政 府 正 式 簽 署 三 方 戰 略 合 作 協 議 （「協議」），並就後續共建「聯康 — 溫醫大轉化醫學聯合創新實驗室（」「聯合實驗 室」）事宜進行探討。此次合作有助於強化本集團在皮膚 ...

Group 1 - The National Medical Products Administration (NMPA) of China has approved the listing application for the ophthalmic product JinYinKang® (Diquafosol Sodium Eye Drops) by the company, with the approval number "国药准字H20254149" [1] - JinYinKang® represents the second ophthalmic drug in the company's pipeline, following JinYinShu®, and aims to provide diverse treatment options for patients with dry eye syndrome [1] - The product works by activating the P2Y2 receptor to stimulate tear and mucin secretion, improving tear film stability and repairing corneal epithelial damage in patients diagnosed with dry eye and associated corneal epithelial defects [1] Group 2 - The company has established a new production base in Dongguan, featuring integrated Blow-Fill-Seal (BFS) technology and a sterile production line, ensuring drug quality and convenience with preservative-free, single-dose packaging [1] - Strategic partnerships with active pharmaceutical ingredient (API) suppliers have been formed to acquire high-quality raw materials at costs below the industry average [1] - The company has expanded its sales team and integrated online and offline channel resources to cover hospitals, pharmacies, and major e-commerce platforms, ensuring rapid market penetration and competitiveness for JinYinKang® [1] Group 3 - The approval of JinYinKang® is expected to create a synergistic effect with JinYinShu®, driving sustained growth in the company's performance [2] - JinYinShu® is targeted to be included in medical insurance coverage by the end of 2025, enhancing the accessibility and market penetration of the company's ophthalmic drugs [2] - The diversification of sales channels and product pipeline will strengthen the company's position in the ophthalmic market [2]